Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study

Autor: Bijal D. Shah, Armin Ghobadi, Olalekan O. Oluwole, Aaron C. Logan, Nicolas Boissel, Ryan D. Cassaday, Thibaut Leguay, Michael R. Bishop, Max S. Topp, Dimitrios Tzachanis, Kristen M. O’Dwyer, Martha L. Arellano, Yi Lin, Maria R. Baer, Gary J. Schiller, Jae H. Park, Marion Subklewe, Mehrdad Abedi, Monique C. Minnema, William G. Wierda, Daniel J. DeAngelo, Patrick Stiff, Deepa Jeyakumar, Jinghui Dong, Sabina Adhikary, Lang Zhou, Petra C. Schuberth, Imi Faghmous, Behzad Kharabi Masouleh, Roch Houot

Publikováno v: Journal of hematology & oncology, vol 15, iss 1
Journal of Hematology and Oncology
Journal of Hematology and Oncology, 2022, 15 (1), pp.170. ⟨10.1186/s13045-022-01379-0⟩

Background Brexucabtagene autoleucel (KTE-X19) is an autologous anti-CD19 CAR T-cell therapy approved in the USA to treat adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (R/R B-ALL) based on ZUMA-3 study results. W

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5e535f707491b52d5e9e38e372d3320
https://pubmed.ncbi.nlm.nih.gov/36494725

Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease

Autor: Rachid Mojaat, Emmanuelle Plaisier, Philippe Remy, Philippe Lang, Karine Dahan, Vincent Audard, Pierre Ronco, Helene Munyentwali, Georges Deschênes, Khedidja Bouachi

Publikováno v: Kidney International
Kidney International, Nature Publishing Group, 2013, 83 (3), pp.511-6. ⟨10.1038/ki.2012.444⟩
Kidney International, 2013, 83 (3), pp.511-6. ⟨10.1038/ki.2012.444⟩

International audience; Development of steroid dependency in patients with nephrotic syndrome may require a long-term multi-drug therapy at risk of drug toxicity and renal failure. Rituximab treatment reduces the steroid dosage and the need for immun

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12d7e8565a643f2c3287cc1f896a8e56
https://doi.org/10.1038/ki.2012.444

Increasing Flt3L availability alters composition of a novel bone marrow lymphoid progenitor compartment

Autor: Antonius G. Rolink, Melanie Rauch, Rhodri Ceredig, Gina Balciunaite

Publikováno v: Blood
Blood, American Society of Hematology, 2006, 108 (4), pp.1216-22. ⟨10.1182/blood-2005-10-006643⟩

We have recently described a CD19– B220+CD117low bone marrow subpopulation with B, T, and myeloid developmental potential, which we have called “early progenitors with lymphoid and myeloid potential” or EPLM. These cells also expressed Fms-like

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2baf8648f2e8d04406b25f98075b8369
https://www.hal.inserm.fr/inserm-00473513

An anti-CD19 antibody coupled to a tetanus toxin peptide induces efficient Fas ligand (FasL)-mediated cytotoxicity of a transformed human B cell line by specific CD4+ T cells

Autor: Yu Z, Gérard Eberl, S Jiang, Giampietro Corradin, Pascal Schneider, Jean-Pierre Mach

Publikováno v: Clinical and Experimental Immunology
Clinical and Experimental Immunology, Wiley, 1998, pp.173-8

SUMMARYTreatment of B cell lymphoma patients with MoAbs specific for the common B cell marker (CD20) has shown a good overall response rate, but the number of complete remissions is still very low. The use of MoAbs coupled to radioisotopes can improv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1960dc581bb23ab63b43425a9243aa20
https://hal-pasteur.archives-ouvertes.fr/pasteur-01402850